Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Evaluation and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Presentation (NASDAQ:LXEO) 10-24-2026.

Seeking Alpha Markets · Source